DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS FOR AFFECTING TUMOR GROWTH USING OXYGEN MIMETIC AGENTS

Abstract: The present invention relates generally to the use of oxygen mimetic compounds or agents to limit the growth of hypoxic tissue, such as solid tumors, through the delivery of cytotoxic agents, and/or a reduction in the amount of released pro-angiogenic factors responsible for new blood vessel formation.

Description: (A) TITLE DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS FOR AFFECTING TUMOR GROWTH USING OXYGEN MIMETIC AGENTS (B) CROSS-REFERENCE TO RELATED APPLICATIONS Not Applicable (C) FEDERAL SPONSORSHIP Not Applicable (D) BACKGROUND OF THE INVENTION (Dl) FIELD OF THE INVENTION The present invention is directed to delivering an agent with oxygen mimetic properties to hypoxic tissue such as tumor cells and affecting the growth of the hypoxic tissue. The agents of the present invention selectively target and incorporate into hypoxic tissue, and by inherent properties of the agent itself or through the cytotoxic action of agents conjugated to the oxygen mimetic agent, accomplish growth inhibition of the hypoxic tissue and/or cell killing. The diagnostic compositions and methods include oxygen mimetic agents conjugated to radionuclides, such as Technicium-99, Iodine-123, or Iodine-131, to provide a means of imaging the cancerous tissue. Comparison of the amounts of hypoxic tissue before and after various cancer therapies provides a measure of treatment efficacy. (D2) DESCRIPTION OF RELATED ART Anti-tumor therapy has, in general, consisted of radiotherapy, chemotherapy and irnmunotherapy. Radiotherapy can involve direct exposure of the cancerous tissue to radiation delivered by a targeting agent to the tumor site with minimal exposure of -1- C0NFIRMATI0N COPY normal tissue to radiation damage or radiation delivered to general areas of the body with consequent increased exposure of normal tissue to radiation. Chemotherapy involves delivery of cytotoxic agents to the tumor site with the aim of preferentially destroying cancerous tissue over normal tissue. The literature is replete with examples of side effects to both radiation therapy and chemotherapy. Immunotherapy has been studied extensively over the past several years with varied results, depending on the approach taken. Unfortunately, it is generally the case that tumor specific antibodies will not in and of themselves exert sufficient anti-tumor effects to make them useful in cancer therapy. In contrast with their efficacy in lymphomas, immunotoxins have proven to be relatively ineffective in the treatment of solid tumors such as carcinomas. The principal reason for this is that solid tumors are generally impermeable to antibody-sized molecules: specific uptake values of less than 0.001% of the injected dose/g of tumor are not uncommon in human studies. Furthermore, antibodies that enter the tumor mass do not distribute evenly for several reasons. Firstly, the dense packing of tumor cells and fibrous tumor stromas present a formidable physical barrier to macro-molecular transport and combined with the absence of lymphatic drainage create an elevated interstitial pressure in the tumor core which reduces extravasation and fluid convection. Secondly, the distribution of blood vessels in most tumors is disorganized and heterogeneous, so some tumor cells are separated from extravasating antibody by large diffusion distances. Thirdly, all of the antibody entering the tumor may become absorbed in perivascular regions by the first tumor cells encountered, leaving none to reach tumor cells at more distant sites. Hypoxia defines a metabolic state in which the concentrations of oxygen in tissue are lower than required to sustain normal cellular metabolism yet are not totally lacking oxygen, as would be found in a state of anoxia. Tissues are hypoxic if molecular oxygen (Oj) levels are below normal, but not at zero (anoxia). There are substantial fluctuations in 0 2 levels among and within various tissues under normal perfusion, so that there is no universal base-line criterion for hypoxia. For example, radiobiological hypoxia is most pronounced at 0 2 levels below 1000 ppm (0.1%; < 0.1 mm Hg p0 2 ) but in other tissues, metabolic effects may be apparent at 0 2 concentrations just below the venous blood concentration (< 30 mm Hg p0 2 ). Hypoxia may develop in tissues because of transient capillary occlusion, vascular or arterial damage, or inadequate angiogenesis. Tumor hypoxia occurs through several mechanisms. The most readily apparent mechanism is rapid, uncontrolled growth of the tumor tissue such that the existing nutritional stores and blood supply (oxygen) are insufficient to support cellular processes. Oxygen deficiency is associated with a number of physiological and pathological conditions. The concentration of oxygen in healthy cells varies substantially from tissue to tissue, with lowest concentrations occurring in cells farthest from capillaries in the liver. In disease, hypoxia may occur as a result of aggressive tissue proliferation together with inadequate angiogenesis, a common condition in solid tumors (cancer). Hypoxia may also occur as a result of ischemia (decreased blood supply) because of vascular rupture (stroke), vascular blockage (heart attack) or vascular or arterial disease (diabetes). Cells that are hypoxic but alive exhibit a number of unique properties, including increased resistance to radiation, and up-regulation of biological factors that favor or promote re-vascularization. Low levels of oxygen and insufficient blood supply cause the tumor cells to release agents that, directly or indirectly, promote the formation of new blood vessels (angiogenesis). Released agents that promote angiogenesis include Hypoxia-Inducible Factor alpha (HLF-1), Vascular Endothelial Growth Factor (VEGF), Fibroblast Growth Factor (FGF), angiogenin, Hepatocyte Growth Factor (HGF), Insulin-like Growth Factors, Interleukin-8 (IL-8), Platelet Activating Factor (PAF), Platelet-Derived Endothelial Growth Factor (PDEGF), Platelet-Derived Growth Factor, Transforming Growth Factor-α (TGF-α), Transforming Growth Factor-β (TGF- β), Tumor Necrosis Factor-α (TNF-α). VEGF, also known as Vascular Permeability Factor (VPF) is likely the most potent pro-angiogenic molecule of the above list (Brown et al, EXS, 79:233- 269, 1997). In response to lower levels of oxygen, tumor cells undergo a "stress response" and display lower radiation sensitivity. This oxygen effect in clinical radiotherapy has proven to be a significant obstacle to effective treatment. Under conditions of low oxygen levels, cell phenotypes are expressed which favor tumor progression through mechanisms involving resistance to therapy in addition to increased angiogenesis. Molecular oxygen contributes to the lethal effects of low linear-energy-transfer (LET) ionizing radiation, and is therefore a vital component of successful radiation therapy of cancer using therapeutic x-rays. Oxygen-deficient cells require approximately three times more radiation for a lethal effect than for fully oxygenated cells. This Oxygen effect' is due to the reactivity of oxygen with molecules that have unpaired electrons (free radicals) and to the reactivity of singlet oxygen and other oxygen radical species. Reaction between oxygen and free radicals results in the formation of peroxy species which can inhibit cellular repair mechanisms, and which can react with other molecules such as DNA to inactivate them. Radiation therapy generates high concentrations of short-lived reactive species such as solvated electrons, hydrogen radicals and hydroxy radicals. In the presence of molecular oxygen there is also a high probability that they will interact to produce oxygen radical anions (superoxide), peroxy radicals and hydroperoxy radicals, which have longer half-lives and which react with tissue macro molecules. These reactions result in the production of repair-resistant 'chemical adducts' which contribute to cell (tumor) death. Certain classes of molecules will similarly form repair resistant adducts in the absence of oxygen; these compounds are called radiosensitizers. Nitroimidazoles are among the most effective and least toxic radiosensitizers developed to date. Exposure of cancerous tissue to high levels of oxygen reverses the resistance of the tumor to radiation therapy. In the presence of normal to high levels of oxygen, cancer cells initiate a rapid growth phase, essential for efficient killing by the radio- therapeutic agent. Under such circumstances the cancer cells divide rapidly and release cancer-specific molecules into the blood stream, detectable using standard assay techniques. Targeting of hypoxic tissue such as solid tumors has been accomplished with a variety of compounds, which selectively incorporate into the hypoxic cells. One such example is iodoazomycin arabinoside (IAZA) (Groshar et al, Journal of Nuclear Medicine, 34:885-888, 1993). This molecule has been shown to selectively incorporate into hypoxic cells of solid tumors such as small-cell lung carcinoma, non-small-cell lung carcinoma, glioblastoma, and cancers of the Head and Neck. Previous studies have used radiolabeled IAZA as a diagnostic probe to image hypoxic tumors. 123 I-LAZA was well tolerated in individuals with various malignancies when used as a tool to image hypoxic tissue (Urtasun et al, British Journal of Cancer, Supplement, 27:S209-S212, 1996). The doses used in imaging are much lower than would be used in therapy. Some studies have shown superior therapeutic efficacy using tumor directed internalizing antibodies labeled with Auger-electron emitters such as 125 Iodine ( 125 I) in comparison to beta-emitters such as 131 I (Behr et al, International Journal of Cancer, 76:738-748, 1998). Higher doses of the Auger-electron emitters are tolerated by the recipient resulting in improved therapeutic outcome. The lower toxicity of the Auger- emitters may be due to the short path length of the low-energy electrons (micrometers) versus the longer path length of the beta-emitters (millimeters). Although Auger- emitters are better tolerated (i.e. shorter path length of the low-energy electrons), treatment efficacy is greatly improved if the agents carrying the Auger-emitters are internalized by the tumor cell leading to improved targeting of the tumor cell DNA. Targeting of hypoxic tissue with Auger-electron labeled oxygen mimetics such as 125 I- IAZA selectively damages the DNA of the hypoxic tissue in turn preventing release of pro-angiogenic factors such as HIF-1 and VEGF. However, use of 131 I-conjugated oxygen mimetic (i.e. 131 I-IAZA), due to its slightly longer radiation path length, in some cases provides better therapeutic efficacy by destroying not only the hypoxic tissue responsible for the uptake of the agent, but also tissue that is immediately adjacent to the cancer tissue. This tissue is most often cancerous tissue that is slowly progressing to a hypoxic state. The efficacy of treatment varies between the different cancers, between the various therapies, between individuals receiving the same therapy, and even within the neoplasm itself with some cancer cells more resistant to a given therapy than others. Thus, often times patients receive a therapy that is ineffective in treating the malignancy, yet the patient still suffers the side-effects of the therapy. These side effects are not trivial and contribute significantly to the morbidity of the cancer patient including hair loss, loss of taste, dry mouth, extreme nausea, cachexia, and damage to the bone marrow. It is therefore of the utmost importance to choose the most appropriate therapy and to monitor the efficacy of that therapy in a timely manner in order to minimize unnecessary patient discomfort. Current methods for monitoring cancer therapy include Magnetic Resonance Imaging (MRI), radiographic analysis (X-ray), CAT scans and manual palpation. Although these methods are readily available, they rely on detecting a measurable reduction in tumor size and therefore require the physician to wait for a significant period of time post therapy before attempting assessment. Should the patient be receiving a therapy that is ineffective against that particular neoplasm, they are destined to suffer the side effects of the therapy until the physician determines that the treatment is not working, which can be as long as three to four weeks. Rapidly growing neoplasms become hypoxic due to the cancerous tissue overgrowing the existing blood and oxygen supply. The current invention encompasses methods for rapidly determining the effectiveness of cancer therapy through the use of oxygen mimetic agents conjugated to radionuclides. (E) SUMMARY OF THE INVENTION The present invention relates to delivery of oxygen mimetic molecules, such as IAZA to hypoxic tissue, such as a tumor mass, as a means to selectively reduce cell growth and/or kill the target tissue. The present invention also relates to the use of oxygen mimetic molecules bound to radionuclides as a means of monitoring the efficacy of various cancer therapies. A hypoxic state in tumor tissue leads to enhanced resistance to radio- and chemotherapeutic agents, in addition to initiation of new blood vessel growth through the release of various agents that promote angiogenesis. Delivery of an agent that specifically targets hypoxic tissue and also has oxygen mimetic properties is most desirable. Addition of the oxygen mimetic molecule to the hypoxic tissue (e.g. tumor) interferes with the natural compensatory mechanism for hypoxic stress (i.e. the calling of new blood vessels, angiogenesis), in turn limiting further tumor growth. For example release of agents such as HIF-1 and/or VEGF are reduced thereby limiting the formation of new blood vessels feeding the tumor. The oxygen mimetic molecule can be delivered in a conjugated or un-conjugated form. Preferred agents to which the oxygen mimetic is conjugated include cytotoxic agents, radioactive agents and oligonucleotides. Addition of a radio-conjugated oxygen mimetic (e.g. 125 I-IAZA, 131 I-IAZA) to hypoxic tissue accomplishes several tasks: T) the hypoxic tissue of the tumor is targeted preferentially, II) the radiosensitivity of the tumor tissue is increased due to the oxygen mimetic properties of the agent, III) the Auger-emitting 125 I conjugate selectively targets the hypoxic cells, which have internalized the agent, IV) the 131 I conjugate destroys hypoxic tissue and marginally hypoxic tissue through the "crossfire" effect of the 131 I isotope, V) release of agents promoting blood vessel growth (e.g. VEGF) are reduced. Typical vascularized tumors are the solid tumors, particularly carcinomas, which require a vascular component for the provision of oxygen and nutrients. Exemplary solid tumors to which the present invention is directed include, but are not limited to, carcinomas of the lung, breast, ovary, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder, prostate, thyroid, squamous cell carcinomas, adenocarcinomas, small cell carcinomas, melanomas, gliomas, neuroblastomas, and the like. (F) DESCRIPTION OF DRAWINGS Not applicable (G) DETAILED DESCRIPTION OF THE INVENTION The present invention provides compositions and methods for delivering agents with oxygen mimetic properties to hypoxic tissue, such as tumor cells, thereby affecting the growth of the hypoxic tissue. In preferred embodiments of the invention, the agents with oxygen mimetic properties are nitroimidazole or nitroimidazole-like compounds, and they are allowed to incorporate in the hypoxic tissue, thus inducing an altered state. In accordance with the present invention, the altered state leads to a mediation in the amount of released pro-angiogenic factors. As used herein, mediation refers to an increase, a decrease, or combinations thereof. In accordance with one embodiment of the present invention, there is provided a method for measuring the effectiveness of therapy intended to kill neoplastic tissue or cells in a mammal, comprising the steps of obtaining molecules with oxygen mimetic properties, which bind preferentially to hypoxic cancerous tissue, the oxygen mimetic agent being labeled; contacting the labeled oxygen mimetic with tissue of a mammal that has received therapy to kill neoplastic cells in vivo; and determining the effectiveness of therapy by measuring the binding of the labeled oxygen mimetic agent to the remaining hypoxic cancerous tissue. In a preferred embodiment of the invention, the oxygen mimetic agent binds specifically to hypoxic cancer tissue or cells, and the contacting step preferably comprises administering the labeled oxygen mimetic to a mammal in vivo. Preferred labels include radionuclides, magnetic resonance enhancing agents, and radiopaque materials, and preferred methods for measuring binding or incorporation of labeled oxygen mimetic to hypoxic tissue include imaging techniques including scintigraphic, magnetic resonance and radiographic imaging. The present invention provides compositions and methods for monitoring the efficacy of cancer therapy by delivering labeled agents with oxygen mimetic properties to hypoxic tissue, such as tumor cells, pre- and post-treatment, thereby providing a measure of tumor tissue reduction based on the binding or incorporation of the oxygen mimetic agent into the remaining hypoxic neoplastic tissue. The present invention also provides compositions and methods for measuring hypoxia in vivo, preferably hypoxia related to and/or associated with cancer, by delivering labeled agents with oxygen mimetic properties to hypoxic tissue, such as tumor cells, pre- and post-treatment, thereby providing a measure of localized hypoxia based on the binding or incorporation of the oxygen mimetic agent into the remaining hypoxic tissue (e.g., neoplastic tissue). The oxygen mimetic agent is constructed such that the agent is preferentially incorporated into hypoxic tissue. In a preferred embodiment of the invention, the agent would preferentially incorporate into tumor cells, in vivo. Examples of oxygen mimetic agents suitable for radiolabeling include, but are not limited to: IAZA, iodoazomycin galactoside (IAZG), iodoazomycin pyranoside (IAZP), fluoroiodoazomycin pyranoside (FIAZP), IAZGlu (a glucoside), l-(4-iodo-4- deoxylyxopyranosyl)-2-nitroimidazole (IAZLP), iodoazomycin riboside (IAZR), iodovinylmisonidazole (IVM), 2-nitroimidazolyl)-l-(iodo-4-hydroxyphenyl) ethanols (NIHE's), 2-(2-nitroimidazolyl)iodohydroxyacetophenones (NIHA's), [2-(4- iodophenoxy)ethyi]-2-nitroimidazole (IPENI), l-(2-hydroxy-3-methoxy)-4(5)-iodo-5(4)- nitroimidazole (I-nitroMHPI's), iodometronidazole, 4-bromomisonidazole (Br-MISO), and misonidazole (MISO). An exemplary oxygen mimetic would be iodoazomycin arabinoside (IAZA). In a further preferred embodiment of the invention, the oxygen mimetic agent would be radiolabeled with Auger electron emitters. Exemplary Auger-emitters include, but are not limited to: 125 Iodine, 123 Iodine. In a further preferred embodiment of the invention, the oxygen mimetic agent would be radio labeled with 131 Iodine. For imaging purposes any of the well know medical radionuclides can be used. Suitable radionuclides include 131 Iodine, 123 Iodine, 125 Iodine, ιπ Indium, 113 Indium, 7 Gallium, "Technicium or other suitable gamma-emitters. Radiopaque materials also may be used to label the oxygen mimetic agent. Suitable radiopaque materials include, but are not limited to iodine compounds, barium compounds, gallium compounds, and thallium compounds. Specific examples of radiopaque materials include barium, diatrizoate, ethiodized oil, gallium citrate, iocarmic acid, iocetamic acid, iodamide, iodipamide, iodoxamic acid, iogulamide, iohexol, iopamidol, iopanoic acid, ioprocemic acid, iosefamic acid, ioseric acid, iosulamide meglumine, iosumetic acid, iotasul, iotetric acid, iothalamic acid, iotroxic acid, ioxaglic acid, ioxotrizoic acid, ipodate, meglumine, metrizamide, metrizoate, propyliodone, and thallous chloride. Materials that can be detected by or that enhance the effects of magnetic resonance imaging equipment also may be conjugated to the oxygen mimetic agent of the present invention. Suitable magnetic resonance-enhancing compounds include, but are not limited to, gadolinium, copper, iron, and chromium. In an embodiment of the invention, alpha-emitting and beta-emitting radionuclides may be used. Such compounds include, but are not limited to, 1-131, Y- 90, Cu-67, Au-198, and P-32. As used herein, "administering" refers to any action that results in exposing or contacting a composition containing a binding agent with a pre-determined cell, cells, or tissue, typically mammalian. Administering may be conducted in vivo, in vitro, or ex vivo. For example, a composition may be administered by injection or through an endoscope or catheter. Administering also includes the direct application to cells of a composition according to the present invention. For example, during the course of surgery, the vasculature of tumor or hyperplastic tissue may be exposed. In accordance with an embodiment of the invention, the exposed cells or vasculature may be exposed directly to a composition of the present invention, e.g., by washing or irrigating the surgical site, and/or the cells. The composition may also include pharmaceutically acceptable carriers. Pharmaceutically acceptable carriers include but are not limited to saline, sterile water, phosphate buffered saline, and the like. Other buffering agents, dispersing agents, and inert non-toxic substances suitable for delivery to a patient may be included in the compositions of the present invention. The compositions may be solutions suitable for administration, and are typically sterile and free of undesirable particulate matter. The compositions may be sterilized by conventional sterilization techniques. For example, the therapeutic or diagnostic agent may be introduced into the patient by an intravenous, subcutaneous, intraperitoneal, intrathecal, intravesical, intradermal, intramuscular, or intralymphatic route. The composition may be in solution, tablet, aerosol, or multi-phase formulation forms. Liposomes, long-circulating liposomes, immunoliposomes, biodegradable microspheres, micelles, or the like may also be used as a carrier, vehicle, or delivery system. The clinician may compare the responses associated with these different routes in determining the most effective route of administration. The invention should not be limited to any particular method of introducing the binding agent into the patient. Administration may be once, more than once, and over a prolonged period. As the compositions of this invention may be used for patients in a serious disease state, i.e., life threatening or potentially life-threatening, excesses of the binding agent may be administered if desirable. Actual methods and protocols for administering pharmaceutical compositions, including dilution techniques for injections of the present compositions, are well known or will be apparent to one skilled in the art. Some of these methods and protocols are described in Remington's Pharmaceutical Science, Mack Publishing Co. (1982). The composition may be administered in combination with other agents or regimens to effect tumor arrest, regression or killing. The composition may be administered in the presence of agents that enhance the uptake of the composition such as permeating agents. One skilled in the art will also recognize that liposomes, nanospheres, micelles, or microspheres may be used to administer a composition, and that such administration may result in a therapeutically desirable benefit. Definitions: As used herein, "oxygen mimetic" refers generally to the group of molecules known as nitroimidazoles, which undergo reversible 1-electron reductions in hypoxic tissue. One or more of these reduced products can react chemically with cellular components to form non-diffusible adducts. As used herein, hypoxic tissue refers to any tissue, including cancerous tissue that contains lower levels of oxygen (e.g., < 10 mm Hg) than normally found in that tissue. As used herein, adjunct therapy refers to any treatment used in combination with, or as follow-up to, an existing therapeutic regimen. As an example, Head and Neck tumors treated with an existing chemotherapeutic regimen such as cisplatin, cyclophosphamide and doxorubicin, as an example, could be concomitantly or treated in follow-up with the oxygen mimetic therapy of the present invention. EXAMPLES Example 1. Using a modification of the method published by Sakaguchi et al (Journal of Medical Chemistry, 26:20-24, 1983) azomycin arabinoside was prepared by coupling azomycin to a 1-bromo-protected sugar. Azomycin arabinoside was iodinated using the triphophine/iodine method of Jette et al (Radiation Research, 105:169-179, 1986). Azomycin arabinoside was synthesized by coupling the corresponding protected 1-bromo sugar to azomycin using a modification of the published procedure. Although the α-bromo anomer was used to produce the β-nucleoside, and contrary to earlier reports of β-nucleoside formation, the α-nucleoside has been confirmed to be the major product of the coupling and, when C5 '-iodinated, to be the product referred to in the literature as IAZA. l-α-D-(5-Iodo-5-deoxy-arabinofuranosyl)-2-nitroimidazole (IAZA) was initially radiolabeled by exchange from Na*I in DMF, but for patient studies the pivalic acid melt was used because of greater radiochemical yield ( ~ 90%) and higher chemical and radiochemical purity (both > 92%). Conformational differences between IAZR and IAZA, resulting from the change in configuration at C-l' (from β to α) and C-2' (from 'ribo - down' in IAZR to 'arabino - up' in IAZA) introduced substantial physicochemical changes. The P of IAZA (4.98) is double that for IAZR, but the in vitro rate of hypoxia-dependent adduct formation was identical to IAZR rates, and radiosensitization and cytotoxicity properties were similar between the two nucleosides. Example 2. Growth of tumor cells such as EMT-6 (mouse fibrosarcoma), LnCAP (human prostate cancer) and MCF-7 (human breast carcinoma) under hypoxic conditions demonstrated selective uptake of oxygen mimetic molecules such as IAZA, 131 I-LAZA, and 125 I-IAZA. Example 3. Patients with various solid tumors were imaged with 123 I-IAZA to identify hypoxic tissue in the tumor mass. Of 23 Small Cell Lung Carcinomas imaged, 15 demonstrated uptake of the 123 I-IAZA in the tumor tissue. Of 6 glioblastomas imaged, 2 demonstrated uptake of 123 I-IAZA in the tumor tissue. Of 20 Head and Neck cancers imaged, 10 demonstrated uptake of the 123 I-IAZA in the tumor tissue. Of 4 Astrocytomas imaged, 1 demonstrated uptake of the I23 I-IAZA in the tumor tissue. Of 1 Rhabdomyosarcomas imaged, 1 demonstrated uptake of the 123 I-IAZA in the tumor tissue. Example 4. 131 I-IAZA is used to image various tumors in human subjects and demonstrates selective incorporation in these hypoxic tissues. Imaging studies will be performed in 5 subjects with tumors demonstrating defined areas of hypoxia. 131 I-IAZA is administered by slow intravenous injection; in previous studies no side effects to the injection have been noted; 200-300 MBq will be administered and the patient monitored after injection with measurement of pulse and blood pressure and observation. Planar whole body images will be acquired immediately after injection and at 4, 24, 48, 72 and 96 hours after injection. Each set of images will take approximately 30 minutes. No SPECT images will be required for this protocol. Images will be acquired on a Marconi Axis gamma camera interfaced to an Odyssey computer. A high energy collimator will be used for all images and all images acquired to time. Prior to imaging, and at each daily imaging time point, blood samples will be collected for CBC and SMA12 to confirm the lack of adverse events after injection of the radiopharmaceutical labeled with Iodine-131. No changes were observed after 123 I- IAZA injection. Dosimetry calculations will be performed using the MIRD formalism and patterns of uptake and distribution reviewed from the derived images. The key data derived from this study will be (a) retention of 131 I-IAZA in tumor and (b) whole body dosimetry calculations. A successful outcome will be demonstration of prolonged uptake and retention, low whole body dosimetry and adequate tumor dosimetry. Example 5. An oxygen mimetic agent such as that produced in Example 1 (IAZA) can be labeled with 1-125, 1-131 or 1-123 by standard procedures as outlined by Weibe et al (US patent 5401490). Example 6. 131 I-IAZA is used to image solid tumors such as tumors of the Head and Neck, prostate tumors, small cell lung carcinomas, and the like, prior to initiating cancer therapy. Radiographic analysis using the labeled oxygen mimetic provides a baseline reading of the location and extent of hypoxic neoplastic tissue. The subject is then exposed to the anti-tumor therapy and after waiting an appropriate period of time for the therapy to have taken effect, as would be known to those skilled in the art, the tumor is again imaged to measure the incorporation of the 131 I-IAZA into the tumor tissue. Reduction in 131 I-IAZA-incorporation is indicative of a desirable therapeutic regimen. An increase in the area of 131 I-IAZA-incorporation may prompt higher dosage of the therapeutic agent or abandoning of the current therapy in favor of a more promising therapy. In this way, therapy can be adjusted on an individual basis to maximize tumor killing while minimizing undesirable treatment side effects. Example 7. IAZA has been studied in a variety of experimental pathologies. In a photodynamic therapy (PDT) rat prostate tumor model (Copenhagen x Fisher rats bearing both Dunning R3327R), 123 IAZA uptake in regions of PDT-induced hypoxia showed an inverse correlation with 99ra Tc-HMPAO uptake. This provided strong evidence for hypoxia-selective binding of 123 IAZA. These conclusions were recently confirmed in autoradiographic studies of a rat model of cerebral occlusion, in which dual radionuclide autoradiography clearly depicted uptake of 125 IAZAin ischemic areas and (mutually exclusively) uptake of 99m Tc-HMPAO in well-perfused regions. Preliminary imaging studies in a surgical model of canine myocardial ischemia showed uptake of 123 IAZA in ex vivo images but not in in vivo images taken 4 h after dosing. Example 8. In vitro binding rates for azomycin derivatives, for example, Miso [Chapman, et al., Cancer Res., 43:1523-1528 (1983)], increase as a function of their concentration in the culture medium. The azomycin nucleosides demonstrate this property over a similar concentration range (20-1000 μM). This concentration dependency has also been demonstrated in vivo in murine EMT-6 and RIF-1 models. In these studies, 125 LAZA binding was directly proportional to the intraperitoneal dose of 125 IAZA at concentrations of 0.5, 5 and 50 μM, indicating concentration-independent access of the tracer to the hypoxic regions of the tumor and confirming dose-dependent binding. It has also been shown that large iv doses of IAZA, given after iv 125 IAZA, produce a drastic 'wash-out' effect, lowering blood levels dramatically with out affecting tumor uptake to produce tumoπblood ratios of 8.7 at 4 h (compared to 6.3 in controls) in the murine EMT-6 model. Although the impact of dose on uptake in hypoxic tissue has not been systematically investigated in patients, radiopharmacokinetic and radiotracer kinetics in human volunteers who received iv doses of 123 IAZA ranging form 0.1 to 10 mg show no discernible difference in plasma clearance and whole body elimination over this 1000-fold concentration range. Example 9. 125 IAZR was obtained by exchange from Na 125 I in DMF at 84° for 3 h (radiochemical yield 85%). IAZR was approximately 5 times more lipophilic than Miso (P = 2.1 vs. 0.43, respectively), both of which are considerably more lipophilic than the non-iodinated AZR (P =0.04). Introduction of iodine also increased protein binding (from < 1% for Miso and AZR, to 20% for IAZR); radiosensitizer efficacy was increased by 2-3 times over AZR (5-10 times over Miso), and cytotoxicity was about 25 times greater than Miso. In graded hypoxia studies, the rate of adduct formation by IAZR was 2.5-3 times greater than for Miso at concentrations from 10- 100 μM. Example 10. l-(6-Iodo-6-deoxy-β-D-galactopyranosyl)-2-nitroimidazole (LAZG) was designed to have a lower P than IAZA. This was accomplished by using a hexose rather than the pentose sugars of IAZR and IAZA. The non-iodinated nucleoside (AZG) was prepared by coupling the blocked α-bromogalactose with azomycin, and IAZG was prepared by iodination with triphenylphosphine and iodine, using standard work-up procedures. LAZG was reported to have a P of 0.57 and hypoxia-dependent binding rates somewhat lower than for IAZA and Miso in EMT-6 cells in vitro. 125 IAZG (exchange labeling) was initially found to be inferior to IAZA, providing lower tumor uptake and somewhat slower blood clearance after injection into mice bearing implanted EMT-6 tumors. More recent data also ascribe an in vitro binding rate to IAZG that is lower than that for IAZA, thereby providing independent confirmation of the earlier findings. Example 11. l-(4-Iodo-4-deoxy-L-xylopyranosyl)-2-nitroimidazole (IAZP) was synthesized by coupling the protected arabinopyranosyl bromide to azomycin, followed by deblocking and iodination using triphenylphosphine and iodine, with the appropriate work-up. IAZP differs from IAZA in that the sugar is in the pyranosyl (5-carbons and oxygen in the ring) form rather than the furanosyl form, so that both compounds have the C2' & C3' 'arabino' configuration, but significantly, the iodo substituent is on C4', a secondary alkyl iodide in IAZP, rather than as a primary alkyl iodide. This alteration was introduced in order to stabilize the nucleoside against deiodination, without greatly affecting other properties. The configuration of this nucleoside at C was originally assigned as β-, but recent findings have shown, based on NMR and x-ray crystallography, respectively, that the configuration of this nucleoside is the α- form. Schneider also reports the recovery of the D-enantiomer. The P values reported for IAZP, however, are much lower than for IAZA. Example 12. Recently developed 2-nitroimidazole nucleosides with lower P values than IAZA include the glucoside, the 2'-I-arabinoside and the glucuronide. The glucoside (IAZGlu), a hexose glycoside like IAZG, is slightly more lipophilic than IAZG (P = 1.07 vs. 0.57 in this report) but has among the lowest binding rates and provided the lowest tumor:blood ratio. The other new nucleoside, l-(4-iodo-4-deoxylyxopyranosyl)- 2-nitroimidazole (IAZLP) is slightly less lipophilic than IAZGlu, intermediate in binding rate and produced the lowest of the reported tumor: blood ratios in a tumor model. Example 13. The radioiodinated 2-nitroimidazoles (azomycin derivatives) comprise the main body of the literature that deals with agents for scintigraphic detection of tissue hypoxia. It is clear from the literature that ring-halogenated nitroimidazoles (radioiodine or radiobromine) are not chemically or metabolically labile (Br-Miso; 4-1-5- nitroMHPI) and/or have low electron affinity (Iodometronidazole; 4-I-5-nitroMHPI). An advantage of the side-chain-halogenated azomycin derivatives is their relatively narrow range of E^'s, within the range for oxygen-reversible reductions to occur in hypoxic tissues. The molecular design then becomes primarily a matter of adjusting (non-reductive) metabolic and pharmacokinetic properties. Compounds reported to date fall into two general categories viz., misonidazole congeners and azomycin glycosides.

Claims: (H) CLAIMS We claim: 1. A method of treating hypoxic tissue comprising administering a nitroimidazole or nitroimidazole-like agent with oxygen mimetic properties, allowing the agent to incorporate into the hypoxic tissue, and inducing an altered state of the hypoxic cells leading to a mediation in the amount of released pro-angiogenic factors. 2. The method of claim 1, wherein the mammal is a human. 3. The method of claim 2, wherein the nitroimidazole or nitroimidazole-like agents are selected from, but are not limited to, iodoazomycin arabinoside (IAZA), iodoazomycin galactoside (IAZG), iodoazomycin pyranoside (IAZP), fluoroiodoazomycin pyranoside (FLAZP), IAZGlu (a glucoside), l-(4-iodo-4- deoxylyxopyranosyl)-2-nitroimidazole (IAZLP), iodoazomycin riboside (IAZR), iodovinylmisonidazole (IVM), 2-nitroimidazolyl)-l-(iodo-4-hydroxyphenyl) ethanols (NIHE's), 2-(2-nitroimidazolyl)iodohydroxyacetophenones (NIHA's), [2-(4- iodophenoxy)ethyl]-2-nitroimidazole (IPENI), l-(2-hydroxy-3-methoxy)-4(5)-iodo- 5(4)-nitroimidazole (I-nitroMHPI's), iodometronidazole, 4-bromomisonidazole (Br- MISO), and misonidazole (MISO). 4. The method of claim 2, wherein the pro-angiogenic factors include, but are not limited to, Hypoxia-Induced Factor alpha (HIF-1), Vascular Endothelial Growth Factor (VEGF), Fibroblast Growth Factor (FGF), angiogenin, Hepatocyte Growth Factor (HGF), Insulin-like Growth Factors, Interleukin-8 (IL-8), Platelet Activating Factor (PAF), Platelet-Derived Endothelial Growth Factor (PDEGF), Platelet- Derived Growth Factor (PDGF), Transforming Growth Factor-α (TGF-α), Transforming Growth Factor-β (TGF-β), Tumor Necrosis Factor-α (TNF-α). 5. The method of claim 1, wherein mediation in the release of pro-angiogenic molecules comprises reducing the formation of new blood vessels feeding the hypoxic tissue. 6. The method of claim 2, wherein the agent is conjugated to a radioisotope. 7. The method of claim 6, wherein the agent is conjugated to an Auger electron- emitting isotope. 8. The method of claim 6, wherein the agent is conjugated to a beta particle emitting isotope. 9. The method of claim 8 wherein the isotope is 131 I. 10. The method of claim 7, wherein incorporation of the conjugate into the hypoxic tissue further limits release of proangiogenic factors through damage of cellular molecules required for the production of said proangiogenic factors. 11. The method of claim 10, wherein hypoxic tissues are selectively affected over normal tissues due to preferential incorporation of the conjugate into hypoxic tissue and the subsequent low energy effects of the Auger electron emission from the radionuclide. 12. The method of claim 10, wherein hypoxic tissues are selectively affected over normal tissues due to preferential incorporation of the conjugate into hypoxic tissue and the subsequent effects of the beta particle emission from the radionuclide. 13. The method of claim 2, wherein the nitroimidazole or nitroimidazole-like agent is conjugated to an oligonucleotide. 14. The method of claim 13, wherein nitroimidazole or nitroimidazole-like agents are selected from, but are not limited to, IAZA, iodoazomycin galactoside (IAZG), iodoazomycin pyranoside (IAZP), fluoroiodoazomycin pyranoside (FIAZP), IAZGlu (a glucoside), l-(4-iodo-4-deoxylyxopyranosyl)-2-nitroimidazole (IAZLP), iodoazomycin riboside (IAZR), iodovinylmisonidazole (IVM), 2-nitroimidazolyl)-l- (iodo-4-hydroxyphenyl)ethanols (NlHE's), 2-(2- nitroimidazolyl)iodohydroxyacetophenones (NIHA's), [2-(4-iodophenoxy)ethyl]-2- nitroimidazole (LPENI), l-(2-hydroxy-3-methoxy)-4(5)-iodo-5(4)-nitroimidazole (I- nitroMHPI's), iodometronidazole, 4-bromomisonidazole (Br-MISO), and misonidazole (MISO). 15. The method of claim 2, wherein the nitroimidazole or nitroimidazole-like agent is conjugated to a cytotoxic agent. 16. The method of claim 2, wherein administration of the nitroimidazole or nitroimidazole-like agent is performed as an adjunct to other methods of treating solid tumors. 17. The method of claim 6, wherein administration of the nitroimidazole or nitroimidazole-like agent is performed as an adjunct to other methods of treating solid tumors. 18. A composition for treating hypoxic tissue in vivo comprising a nitroimidazole or nitroimidazole-like agents, said agents are one or more agents selected from the group consisting of IAZA, iodoazomycin galactoside (IAZG), iodoazomycin pyranoside (IAZP), fluoroiodoazomycin pyranoside (FIAZP), IAZGlu (a glucoside), l-(4-iodo-4-deoxylyxopyranosyl)-2-nitroimidazole (IAZLP), iodoazomycin riboside (IAZR), iodovinylmisonidazole (IVM), 2-nitroimidazolyl)-l-(iodo-4- hydroxyphenyl)ethanols (NIHE's), 2-(2-nitroimidazolyl)iodohydroxyacetophenones (NIHA's), [2-(4-iodophenoxy)ethyl]-2-nitroimidazole (LPENI), l-(2-hydroxy-3- methoxy)-4(5)-iodo-5(4)-nitroimidazole (I-nitroMHPI's), iodometronidazole, 4- bromomisonidazole (Br-MISO), and misonidazole (MISO); and a pharmaceutically acceptable carrier. 19. A method for measuring the effectiveness of therapy intended to kill tumor cells in vivo, in a mammal, comprising the steps of: obtaining a nitroimidazole or nitroimidazole-like agent with oxygen mimetic properties, said agent being labeled; contacting said labeled agent with hypoxic tissue of a mammal that has received therapy to kill malignant cells in vivo; and determining the effectiveness of said therapy by measuring the incorporation of said labeled agent in said hypoxic tissue. 20. The method of claim 19 wherein said label is a radionuclide. 21. The method of claim 20, wherein said radionuclide is selected from the group consisting of TC-99, 1-123, 1-131, In-Ill and Ga-67. 22. The method of claim 21 where the agent with oxygen mimetic properties include, but are not limited to, iodoazomycin arabinoside (IAZA), iodoazomycin galactoside (IAZG), iodoazomycin pyranoside (IAZP), fluoroiodoazomycin pyranoside (FIAZP), IAZGlu (a glucoside), l-(4-iodo-4-deoxylyxopyranosyl)-2-nitroimidazole (IAZLP), iodoazomycin riboside (IAZR), iodovinylmisonidazole (IVM), 2- nitroimidazolyl)-l-(iodo-4-hydroxyphenyl) ethanols (NIHE's), 2-(2- nitroimidazolyl)iodohydroxyacetophenones (NIHA's), [2-(4-iodophenoxy)ethyl]-2- nitroimidazole (LPENI), l-(2-hydroxy-3-methoxy)-4(5)-iodo-5(4)-nitroimidazole (I- nitroMHPI's), iodometronidazole, 4-bromomisonidazole (Br-MISO), and misonidazole (MISO). 23. The method of claim 2, wherein said label is a radiopaque material. 24. The method of claim 2, wherein said label is a magnetic resonance enhancing agent. 25. The method of claim 2, wherein the incorporation of said labeled agent into said hypoxic tissue is measured by imaging said label in vivo. 26. The method of claim 10, wherein said imaging is scintigraphic imaging. 27. The method of claim 10, wherein said imaging is radiographic imaging. 28. A method for measuring hypoxia in vivo comprising obtaining a nitroimidazole or nitroimidazole-like agent with oxygen mimetic properties, said agent being labeled; contacting said labeled agent with hypoxic tissue in vivo; and measuring the incorporation of said labeled agent in said hypoxic tissue. 29. A method of treating hypoxic tissue comprising administering a first radiolabeled nitroimidazole or nitroimidazole-like agent with oxygen mimetic properties and determining the presence of hypoxic tissue; treating any hypoxic tissue with a second nitroimidazole or nitroimidazole-like agent and allowing the agent to incorporate into the hypoxic tissue; and administering a third radiolabeled nitroimidazole or nitroimidazole-like agent to determine the presence of hypoxic tissue. 30. The method of claim 29 wherein the first, second, or third nitroimidazole, or combinations thereof, is IAZA. 31. The method of claim 29 wherein the second nitroimidazole is radiolabeled.

Inventors: NOUJAIM ANTOINE, STEWART MICHAEL WILLIAM, NOUJAIM, ANTOINE, STEWART, MICHAEL, WILLIAM
Applicants: NOUJAIM ANTOINE, NOVOLYTIC INC, STEWART MICHAEL WILLIAM, NOUJAIM, ANTOINE, NOVOLYTIC, INC., STEWART, MICHAEL, WILLIAM
Application year: 2001
Main classification: A61K31
IPC codes: A61K31, A61K41, A61K49, A61K51, A61P35